Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Equality Clinic of Augusta | UNKNOWN |
Not provided
Not provided
Not provided
Transgender men are individuals born genetically female that have a gender identity that is incongruent with their biological sex. For those who have begun or completed transition, they may present as males but still have a uterus and cervix. Thus far, no distinction has been made between routine cervical cancer screening guidelines in non-transgender women and those for transgender men, despite wide variations in sexual practices, including lifelong vaginal abstinence. The purpose of this study is to offer transgender men seen at clinic visits self-collected HPV testing to evaluate for improved cervical cancer screening rates, as well as a survey to further investigate sexual practices, rates of appropriate screening prior to being offered self-collection, and barriers to obtaining appropriate care.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HPV Testing | Experimental | Will perform HPV testing with self-collected specimen |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HPV testing | Diagnostic Test | will perform HPV testing with self-collected specimen |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of cervical cancer screening | Evaluate whether implementation of HPV DNA self swabs will increase rates of cervical cancer screening among transgender men by percentage of trans men who obtain screening through the study | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| incidence of barriers to care | Determine which barriers contribute most to lack of cervical cancer screening among transgender men. Measured via survey. | 1 year |
| incidence of high risk sexual practices |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Must be transgender masculine identifying with uterus and cervix.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jan 29, 2024 | |
| Reset | Jul 11, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jan 29, 2024 | Jul 11, 2024 |
| ID | Term |
|---|---|
| D014189 | Transsexualism |
| D002583 | Uterine Cervical Neoplasms |
| ID | Term |
|---|---|
| D019529 | Sexuality |
| D012725 | Sexual Behavior |
| D001519 | Behavior |
| D014594 | Uterine Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate for the presence of high risk behaviors to determine whether transgender men in our population are at higher or lower risk for HPV-related cervical dysplasia. Measured via survey.
| 1 year |
| rate of HPV vaccination | Evaluate percentage of transgender men that have been vaccinated for HPV. Measured via survey. | 1 year |
| D005833 |
| Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |